Their consistent ammo is:

1. Exhubera failure

2. Balance sheet

3. Focus on its use in Type 1 patients / A1C

4. Focus on "only" being equivalent to the current gold standard RAA

As you mentioned, those who have done their due diligence know that the above items, while having some merit, ultimately are refuted.

I see it as a positive, lower prices, better buying opportunities, greater ROI.

Aside from the ulcer I've developed from this stock over the past couple of years, totally worth it :-)